NEWSAnnouncements & PressEventsPublications17 December 2020 [BioWorld Interview] Hummingbird taps Tempus’ AI for clinical trial in rare NRG1 fusion patients Hummingbird Bioscience is collaborating with Tempus to advance HMBD-001, a differentiated anti-HER3 neutralizing antibody developed using Hummingbird's Rational Antibody Discovery platform, into clinical trials in HER3-driven cancers, including those that... 14 December 2020 Hummingbird Bioscience announces collaboration with Tempus to harness AI-driven precision medicine to accelerate clinical development of HMBD-001 in HER3 driven cancers including NRG1-fusions. SINGAPORE, December 14, 2020 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial... 17 November 2020 Our co-founder and CSO Jerome Boyd-Kirkup speaks with Nancy Hungerford and Tanvir Gill on CNBC Street Signs Asia about Hummingbird’s growing drug discovery and development capabilities, and how they are driving our pipeline of promising therapies for hard to treat conditions, including Covid-19 mAb, an antibody therapy for COVID-19, currently in human trials. A new Covid-19 treatment could become available in Singapore and beyond by early 2021 as homegrown biotech company Hummingbird Bioscience joins major names in making steps to combat the coronavirus ... 27 October 2020 Hummingbird Bioscience receives clinical trial authorization to initiate a Phase I/II clinical trial for Covid-19 mAb, an anti-SARS-CoV-2 antibody for the treatment of COVID-19. A pre-print paper is published on bioRxiv SARS-CoV-2-neutralizing antibodies are promising therapeutics for COVID-19. However, little is known about the mechanisms of action of these antibodies 09 September 2020 Business Insider’s 100 People Transforming Business series, now in its second year, spotlights visionaries who are driving innovative changes Global business has faced unprecedented challenges over the past 12 months, particularly in 2020... 23 August 2020 [Korea Herald Interview] Singaporean antibody firm draws throngs of Korean investors SK Holdings, Mirae Asset, HB, Kiwoom-Shinhan rush to invest in Hummingbird Bioscience... 25 July 2020 Hummingbird Bioscience Scientific Advisory Board member Prof. John Connolly appointed as Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) announced today that John Connolly, Ph.D., has been named chief scientific officer (CSO). In this role, Connolly... 11 May 2020 Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody HMBD-002 for Cancer Clinical Trial Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery of new breakthrough antibody therapeutics for difficult-to-treat conditions, today announced it has signed an agreement with Mycenax Biotech for the production... 20 February 2020 Hummingbird Bioscience closes US$25M investment with Series B extension Hummingbird Bioscience, an innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, has closed an extended Series B funding round of US$25 million. This brings the... 08 January 2020 Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced the publication of preclinical data for its lead... 05 December 2019 Hummingbird Bioscience raises $19 Million in Series B financing to support expansion of its discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced that it has raised US$19 million in a... 16 September 2019 Hummingbird Bioscience announces collaboration with Amgen to co-discover novel therapeutics using Hummingbird’s Rational Antibody Discovery Platform Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, has today announced a multi-target collaboration to co-discover novel antibody therapeutics with Amgen. This partnership brings together Hummingbird’s proprietary drug discovery platform... 08 August 2019 Cancer Research UK and Hummingbird Bioscience join forces to advance novel antibody drug into clinical trials Cancer Research UK, the world’s leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have today (Thursday) announced a partnership to develop Hummingbird’s anti-HER3 antibody drug, HMBD-001,... 25 February 2019 Hummingbird Bioscience Awarded $13.1 Million Grant by the Cancer Prevention and Research Institute of Texas (CPRIT) Hummingbird Bioscience announced today it has been awarded a product development grant totalling $13.1 million by the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support the Phase... 18 February 2019 Hummingbird Bioscience Announces Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma Join its Scientific Advisory Board Hummingbird Bioscience, a systems-biology enabled biotech company focused on the discovery and development of novel cancer therapeutics, today announced James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D., have joined... 09 November 2018 Hummingbird Bioscience to present data on HMBD-001-10D1 at the 30th EORTC-NCI-AACR Annual Meeting Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-001-10D1: A novel humanized anti-HER3 antibody with a unique mechanism... 05 November 2018 Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-002-V4: A novel anti-VISTA antibody that uniquely neutralizes VISTA activity... 10 April 2018 Hummingbird Bioscience to present data on HMBD-002-V4 at the American Association for Cancer Research (AACR) 2018 Annual Meeting Hummingbird Bioscience, a drug discovery and development company focused on novel cancer immuno-therapeutics, will present a poster “HMBD-002-V4, an Anti-VISTA Neutralizing Antibody, Displays Potent Anti-Tumor Efficacy in Combination with Anti-PD(L)1,... 04 December 2017 Hummingbird Bioscience to present data on HMBD-004A at the 59th American Society of Hematology (ASH) Annual Meeting Hummingbird Bioscience, a preclinical -stage drug development company focused on novel cancer immuno-therapeutics, will present a poster “HMBD-004A, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models... 03 May 2017 Hummingbird Bioscience, a rapidly growing therapeutic antibody discovery company today announced it has closed a venture funding round of an undisclosed amount from Decheng Capital Hummingbird is focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics. The company will use the funds raised to advance its lead programs towards... Subscribe To Our NewsSign up to receive more information and to stay up to date with our work. First name or full name Email
